📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
206 analysed today
FollowTelegram
206
Today
149,607
All-time analysed
42,901
Positive
6,659
Negative
91,372
Neutral
8,607
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
40 announcements match the current filters (relevance ≥ 5).
Niva Bupa Elevates Ankur Kharbanda to Deputy CEO and Grants 1.22 Cr ESOPs at ₹72.45
Niva Bupa Health Insurance has announced a significant leadership reshuffle, elevating Ankur Kharbanda to the position of Deputy CEO. The company also approved the grant of 12,251,268 ESOPs to employees at a price of ₹72.45 per share, reflecting a commitment to talent retention. Additionally, two senior executives from Bupa Global have been appointed as Non-Executive Directors, while two others have resigned. These changes indicate a strengthening of the domestic leadership team alongside continued strategic alignment with its global partner, Bupa.
Key Highlights
Mr. Ankur Kharbanda elevated to Executive Director and Deputy CEO effective May 8, 2026.
Grant of 12,251,268 ESOPs at a price of ₹72.45 per share under the ESOP Scheme 2024.
Appointment of Christopher Patrick Carroll (CEO, Bupa Global) and Siobhan Djihan Moynihan (CFO, Bupa Global) as Non-Executive Directors.
Resignation of Non-Executive Directors Penelope Ruth Dudley and Carlos Antonio Jaureguizar Ruiz-Jarabo effective May 8, 2026.
The ESOP grant price of ₹72.45 is derived from the weighted average price in March 2026.
👀 What to Watch
Investors should monitor the impact of the leadership transition on the company's growth trajectory and note the potential equity dilution from the 1.22 crore ESOPs. The internal promotion of the CBO to Deputy CEO suggests a focus on continuity in sales and distribution strategy.
Niva Bupa Announces Leadership Reshuffle and Grant of 1.22 Crore ESOPs
Niva Bupa Health Insurance has announced a significant management overhaul, including the appointment of Christopher Patrick Carroll and Siobhan Djihan Moynihan as Non-Executive Directors effective May 15, 2026. The company elevated Ankur Kharbanda to Deputy CEO, bringing over 20 years of health insurance experience to the role. Concurrently, two directors resigned due to professional commitments, and the board approved the grant of 12,251,268 ESOPs at an exercise price of ₹72.45 per share. These moves aim to strengthen the leadership team while aligning employee incentives with long-term growth.
Key Highlights
Appointment of Christopher Patrick Carroll (CEO, Bupa Global) and Siobhan Djihan Moynihan as Non-Executive Directors.
Elevation of Ankur Kharbanda to Executive Director and Deputy CEO effective May 8, 2026.
Grant of 12,251,268 ESOPs to eligible employees at a grant price of ₹72.45 per option.
Resignation of Non-Executive Directors Penelope Ruth Dudley and Carlos Antonio Jaureguizar Ruiz-Jarabo.
ESOP exercise price of ₹72.45 is based on the weighted average price from March 2026.
👀 What to Watch
Investors should view the internal elevation of the Deputy CEO as a sign of operational continuity, while monitoring the potential equity dilution from the 1.22 crore ESOP grant.
Niva Bupa FY26 PAT Jumps 80% to ₹366 Cr; Q4 Underwriting Profitability Achieved
Niva Bupa reported a strong financial performance for FY26, with Profit After Tax (PAT) surging 80% YoY to ₹366 crore. The company's Gross Written Premium (GWP) grew 27% to ₹8,586 crore, while its retail health market share expanded to 10.1%. Crucially, the Combined Insurance Service Ratio (CISR) improved to 101.4% for the full year, with Q4FY26 hitting 97.4%, signaling a move into underwriting profitability. Operational efficiency also improved, evidenced by a 94.4% claim settlement ratio.
Key Highlights
Profit After Tax (PAT) for FY26 grew 80% YoY to reach ₹366 crore.
Gross Written Premium (GWP) for FY26 stood at ₹8,586 crore, a 27% YoY increase.
Retail health market share increased by 76 basis points to 10.1% in FY26.
Combined Insurance Service Ratio (CISR) improved by 160 bps to 101.4%, with Q4 at 97.4%.
Claim Settlement Ratio improved by 205 basis points to reach 94.4%.
👀 What to Watch
The significant growth in PAT and the achievement of underwriting profitability in Q4 suggest strong operational leverage and scale. Investors should monitor if the company can maintain a CISR below 100% consistently to drive long-term value.
Niva Bupa FY26 PAT Surges 80% to ₹366 Cr; Retail Health Market Share Hits 10.1%
Niva Bupa reported a robust financial performance for FY2026, with Profit After Tax (IFRS) growing 80.4% YoY to ₹366.1 crore. Gross Written Premium (GWP) without 1/n accounting reached ₹9,432.9 crore, a 27.4% increase, driven by a 35% surge in the Retail Health segment. The company successfully expanded its retail health market share to 10.1% while improving its Combined Insurance Service Ratio (CISR) to 101.4% from 103.0% in the previous year. Operational metrics remained strong with a 92.8% renewal rate for retail health indemnity products.
Key Highlights
Profit After Tax (IFRS) increased by 80.4% YoY to ₹366.1 crore in FY2026
Retail Health GWP grew 35% YoY to ₹6,581.5 crore, significantly outperforming the industry health segment growth of 16.7%
Combined Insurance Service Ratio (CISR) improved by 160 bps to 101.4% in FY2026
Retail Health Market Share expanded to 10.1% from 9.4% in FY2025
Individual agent network grew by 58,000 in FY2026 to reach a total of 238,517 agents
👀 What to Watch
Investors should view the strong growth in the high-margin retail segment and improving efficiency ratios as a sign of strengthening market leadership. The company's ability to scale its distribution network while maintaining a high renewal rate of 92.8% suggests sustainable long-term growth.
Niva Bupa Approves FY26 Audited Results; Seeks IRDAI Forbearance for Excess Management Expenses
Niva Bupa's Board has approved the audited financial results for the quarter and fiscal year ended March 31, 2026, alongside IFRS-compliant statements. While the auditors issued an unmodified opinion, they highlighted an 'Emphasis of Matter' regarding the company exceeding Expenses of Management (EOM) limits for FY 2024-25. The company has applied for regulatory forbearance from IRDAI, and the final impact is pending their approval. The adoption of IFRS reporting indicates a move towards global transparency standards.
Key Highlights
Board approved audited financial results for Q4 and the full fiscal year ended March 31, 2026.
Joint Statutory Auditors issued an unmodified opinion on the financial statements.
Company is awaiting IRDAI approval for forbearance on exceeding Expenses of Management (EOM) limits for FY 2024-25.
Audited IFRS Financial Statements for FY26 were approved to align with international reporting standards.
👀 What to Watch
Investors should closely monitor the IRDAI's decision regarding the EOM limit breach, as it could affect regulatory compliance and future expense management strategies. The transition to IFRS reporting should be used to benchmark the company against global health insurance peers.
Niva Bupa Approves FY26 Audited Results; Reports Regulatory Filing for EOM Limit Forbearance
Niva Bupa Health Insurance has approved its audited financial results for the quarter and full year ended March 31, 2026. While the auditors issued an unmodified opinion, they highlighted an 'Emphasis of Matter' regarding the company exceeding the allowable Expenses of Management (EOM) limits for FY 2024-25. The company has applied for regulatory forbearance from IRDAI, and the final financial impact of this breach remains contingent on regulatory approval. Additionally, the Board approved the audited IFRS financial statements for the same period.
Key Highlights
Board approved audited financial results for the quarter and year ended March 31, 2026.
Joint Statutory Auditors S.R. Batliboi & Co. LLP and Nangia & Co. LLP issued an unmodified opinion.
Company has filed for forbearance with IRDAI for exceeding Expenses of Management (EOM) limits in FY 2024-25.
Audited IFRS Financial Statements for FY26 were approved alongside Indian GAAP results.
The Board meeting concluded at 5:00 P.M. IST on May 08, 2026.
👀 What to Watch
Investors should monitor the IRDAI's decision on the EOM forbearance application, as it could impact regulatory compliance and future expense ratios. Review the full financial tables once available to assess core metrics like premium growth and claim ratios.
IRDAI Approves Transfer of 14.62 Crore Equity Shares by Fettle Tone LLP in Niva Bupa
Niva Bupa Health Insurance has received formal approval from the IRDAI for the transfer of up to 14,62,02,091 equity shares. The shares are being transferred by Fettle Tone LLP, an existing investor in the company. This regulatory clearance follows the provisions of the Insurance Act, 1938, and the updated 2024 IRDAI regulations regarding capital structure and share transfers. The move indicates a potential change in the shareholding pattern or an exit/partial exit by a significant investor.
Key Highlights
IRDAI approved the transfer of up to 14,62,02,091 equity shares by Fettle Tone LLP.
The approval was granted under Section 6A of the Insurance Act, 1938.
The transaction complies with IRDAI (Registration, Capital Structure, Transfer of Shares and Amalgamation of Insurers) Regulations, 2024.
Fettle Tone LLP is an existing investor, and this transfer represents a significant volume of the company's equity.
👀 What to Watch
Investors should monitor the identity of the buyer and the transaction price to assess institutional sentiment. While this is a secondary transfer and doesn't dilute equity, a change in major stakeholders can influence long-term strategy.
Niva Bupa Shareholders Approve CEO Remuneration Revision and New Director Appointment
Niva Bupa Health Insurance has successfully passed two key resolutions via postal ballot with near-unanimous shareholder support. The appointment of Mr. Roger William John Davis as a Non-Executive Director was approved with 99.99% of the votes. Furthermore, shareholders greenlit a revision in the remuneration for MD & CEO Krishnan Ramachandran for the 2025-26 financial year. The high approval ratings reflect strong investor confidence in the company's leadership and strategic direction.
Key Highlights
Appointment of Roger William John Davis as Non-Executive Director approved with 99.99% votes in favor.
Remuneration revision for MD & CEO Krishnan Ramachandran for FY 2025-26 passed with 99.99% majority.
Total valid votes cast for the CEO remuneration resolution amounted to 1,56,61,12,697.
The postal ballot process concluded on March 26, 2026, with results officially declared on March 27, 2026.
👀 What to Watch
Investors should view the high approval rates as a sign of management stability and strong institutional backing. No immediate action is required as these are standard governance approvals.
Niva Bupa Receives ₹28.37 Crore Income Tax Demand for AY 2023-24
Niva Bupa Health Insurance has received an Order cum Notice of Demand from the Income Tax Department totaling ₹28.37 crore for the Assessment Year 2023-24. The demand includes a principal tax amount and an interest component of ₹7.10 crore. The dispute arises from the disallowance of certain marketing expenses and provisions for claims Incurred But Not Reported (IBNR). The company intends to contest this demand through an appeal, noting that these issues are largely industry-wide accounting matters.
Key Highlights
Total income tax demand of ₹28,37,45,380 received for Assessment Year 2023-24
Demand includes an interest component of ₹7,10,47,664 under Section 156 of the IT Act
Dispute involves disallowance of marketing expenses under Section 37(1) and IBNR/IBNER claim provisions
Company plans to exercise its right to appeal before the Appellate Authorities
Management characterizes the disallowances as industry-wide issues rather than company-specific failures
👀 What to Watch
Investors should monitor the outcome of the appeal as it pertains to standard insurance accounting practices. While the demand is a negative development, the company's intent to appeal suggests no immediate cash outflow impact.
Niva Bupa Receives IRDAI Show Cause Notice and Letter of Advice for Regulatory Violations
Niva Bupa Health Insurance received a Show Cause Notice (SCN) and a Letter of Advice from IRDAI on February 26, 2026, following an inspection conducted in February 2025. The regulatory communication highlights alleged violations of Master Circulars regarding Health Insurance Business, Policyholder Protection, and Corporate Governance. While the company maintains there is no immediate financial or operational impact, it is currently drafting a response to the SCN. Investors should track this development to see if it results in future penalties or stricter regulatory oversight.
Key Highlights
IRDAI issued a Show Cause Notice and Letter of Advice on February 26, 2026, regarding business and operational aspects.
Alleged non-compliances relate to Master Circulars on Health Insurance Business, Protection of Policyholders Interest, and Corporate Governance.
The company stated there is no quantifiable financial impact on operations or activities at this stage.
Niva Bupa is in the process of submitting a response to IRDAI and implementing advised compliance measures.
👀 What to Watch
Investors should stay cautious and await the final resolution of the Show Cause Notice to assess potential long-term regulatory risks or penalties. Monitor if these compliance measures lead to increased operational costs or changes in business strategy.
Niva Bupa Seeks Approval for CEO Remuneration Revision and New Director Appointment
Niva Bupa Health Insurance has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Roger William John Davis as a Non-Executive Director. The company is also proposing a revision in the remuneration of MD & CEO Mr. Krishnan Ramachandran for FY 2025-26. The proposed fixed pay for the CEO is set at ₹4.13 crore, with additional projected performance bonuses including ₹2.94 crore in cash and ₹6.86 crore in ESOPs. The e-voting period for these resolutions is scheduled from February 25, 2026, to March 26, 2026.
Key Highlights
Proposed fixed remuneration for MD & CEO Krishnan Ramachandran increased to ₹4,12,75,648 for FY 2025-26.
CEO's projected performance-linked pay includes ₹2.94 crore in cash and ₹6.86 crore via ESOPs.
Appointment of Mr. Roger William John Davis as a Non-Executive Director effective from January 29, 2026.
Remote e-voting period starts on February 25, 2026, and ends on March 26, 2026.
Cut-off date for determining shareholder voting eligibility is February 20, 2026.
👀 What to Watch
Investors should evaluate if the proposed executive compensation and ESOP grants are commensurate with the company's financial performance and growth targets. Shareholders eligible as of the cut-off date should participate in the e-voting process to voice their stance on these governance matters.
Niva Bupa Q3 FY26: 9M PAT Jumps 74% to ₹208 Cr; Retail Market Share Hits 10%
Niva Bupa reported a robust financial performance for the nine months ended December 31, 2025, with Profit After Tax (PAT) increasing 74% YoY to ₹208 crores. The company achieved a retail growth rate of 33%, pushing its retail market share to 10%. Operational efficiency improved as the Expense of Management (EOM) ratio dropped to 35% from 39% YoY, while the combined ratio improved by 50 bps to 102.9%. Despite a ₹20 crore one-off impact from new wage codes, the company maintained a strong solvency ratio of 2.49.
Key Highlights
9M PAT surged 74% YoY to ₹208 crores, with Q3 PAT standing at ₹77 crores.
Retail health insurance segment grew by 33% in the 9-month period, with Q3 new business growth at 46%.
Combined Ratio (IFRS) improved by 50 basis points to 102.9% for the 9-month period.
Direct digital channel business witnessed a significant growth of 70% in Q3 FY26.
Solvency ratio remains healthy at 2.49, providing significant cushion for future growth.
👀 What to Watch
Investors should take note of the strong retail growth and improving operating leverage which are driving profitability. The company's ability to gain market share while improving its combined ratio suggests a sustainable growth trajectory.
Niva Bupa Reports 74% YoY Profit Growth to ₹208.3 Cr for 9M FY26
Niva Bupa Health Insurance reported a strong financial performance for the nine months ended December 31, 2025, with net profit surging 74% YoY to ₹20,831 Lakhs. Insurance revenue grew by 35.4% to reach ₹5,71,292 Lakhs, reflecting robust business expansion. Investment income also saw a significant jump of 43% to ₹47,804 Lakhs. While the growth is impressive, the company is currently awaiting IRDAI forbearance for exceeding Expenses of Management (EOM) limits for FY 2024-25.
Key Highlights
Net Profit for 9M FY26 increased by 74.3% YoY to ₹20,831 Lakhs from ₹11,952 Lakhs.
Insurance revenue grew 35.4% YoY to ₹5,71,292 Lakhs compared to ₹4,21,786 Lakhs in the previous year.
Investment income rose to ₹47,804 Lakhs, a 43.1% increase over 9M FY25.
Basic Earnings Per Share (EPS) improved significantly to ₹1.13 from ₹0.69 YoY.
The company has applied for IRDAI forbearance regarding exceeding Expenses of Management (EOM) limits for FY 2024-25.
👀 What to Watch
The company demonstrates strong growth momentum in revenue and profitability; investors should maintain a positive outlook while monitoring the IRDAI's decision on management expense limits.
Niva Bupa Appoints Roger Davis as Director and Aparna Sharma as CS & Compliance Officer
Niva Bupa Health Insurance has announced two key leadership appointments effective January 29, 2026. Mr. Roger William John Davis joins as an Additional Director, bringing 40 years of global financial services experience, including roles as Chairman of BUPA and Sainsbury’s Bank. Additionally, Ms. Aparna Sharma has been promoted to Company Secretary and Compliance Officer (KMP) after successfully overseeing the company's IPO execution. These appointments signify a strengthening of corporate governance and strategic oversight for the recently listed entity.
Key Highlights
Appointment of Mr. Roger William John Davis as Additional Director with 40 years of global financial experience.
Mr. Davis previously served as Chairman of BUPA, Chairman of Sainsbury’s Bank, and on the Board of Barclays Bank PLC.
Ms. Aparna Sharma appointed as Company Secretary and Compliance Officer (KMP) effective January 29, 2026.
Ms. Sharma brings 15+ years of experience and was instrumental in the company's IPO and SEBI compliance implementation.
The board appointments are subject to member approval within three months.
👀 What to Watch
The addition of a high-caliber global leader from the BUPA group to the board is a positive signal for governance and strategic alignment. Investors should monitor how this leadership transition supports the company's post-IPO growth trajectory.
Niva Bupa Appoints Roger Davis as Non-Executive Director and Aparna Sharma as Company Secretary
Niva Bupa Health Insurance has announced two significant leadership appointments effective January 29, 2026. Mr. Roger William John Davis joins as an Additional Non-Executive Director, bringing 40 years of global financial services experience, including former roles as Chairman of BUPA and Sainsbury’s Bank. Additionally, Ms. Aparna Sharma, who has over 15 years of experience in corporate governance and was instrumental in the company's IPO, has been appointed as Company Secretary and Compliance Officer. These appointments are expected to strengthen the company's governance framework and strategic oversight.
Key Highlights
Appointment of Mr. Roger William John Davis as Additional Non-Executive Director effective January 29, 2026
Mr. Davis brings 40 years of experience, having served as Chairman of BUPA and on the Board of Barclays Bank PLC
Ms. Aparna Sharma appointed as Company Secretary and Compliance Officer (KMP) with 15+ years of experience
Mr. Davis previously held leadership roles including MD of India for Jardine Fleming and CEO of BZW Asia Pacific
Director appointment is subject to shareholder approval within three months from the date of appointment
👀 What to Watch
The addition of a high-profile international director like Roger Davis is a positive signal for the company's corporate governance and global strategic alignment. Investors should maintain a positive outlook on the stock as the company strengthens its leadership post-listing.
Niva Bupa Appoints Former Bupa Chairman Roger Davis as Director and New Company Secretary
Niva Bupa Health Insurance has announced the appointment of Mr. Roger William John Davis as a Non-Executive Director, effective January 29, 2026. Mr. Davis brings 40 years of global financial services experience, including roles as Chairman of Bupa and Managing Director of India for Jardine Fleming. Simultaneously, the company appointed Ms. Aparna Sharma as Company Secretary and Compliance Officer, leveraging her 15 years of experience in corporate governance and IPO execution. These leadership additions are aimed at strengthening the company's governance framework and strategic oversight.
Key Highlights
Appointment of Mr. Roger William John Davis as Non-Executive Director with 40 years of global financial services experience
Mr. Davis previously served as Chairman of Bupa, Chairman of Sainsbury’s Bank, and on the Board of Barclays Bank PLC
Ms. Aparna Sharma appointed as Company Secretary and Compliance Officer (KMP) with 15+ years of multifaceted experience
Appointments are effective from January 29, 2026, following a Board meeting held on the same day
The director appointment is subject to shareholder approval within three months
👀 What to Watch
The inclusion of a high-caliber professional like the former Bupa Chairman on the board is a positive signal for governance and strategic alignment. Investors should view this as a strengthening of the leadership team following the company's recent listing.
Niva Bupa 9M FY26 PAT Jumps 74% to ₹208 Cr; Retail Health Market Share Hits 10%
Niva Bupa reported a robust performance for the nine months ended December 31, 2025, with IFRS Profit After Tax (PAT) surging 74.3% YoY to ₹208.3 crore. Gross Written Premium (GWP) grew by 25.9% to ₹6,309.4 crore, significantly outperforming the industry's health segment growth of 15.6%. The company's retail health market share improved to 10.0%, while the Combined Insurance Service Ratio (CISR) showed efficiency gains, narrowing to 102.9% from 103.4% YoY. High renewal rates of 91.8% in the retail health indemnity segment further underscore strong customer retention.
Key Highlights
9M FY26 IFRS PAT increased by 74.3% YoY to ₹208.3 crore from ₹119.5 crore.
Gross Written Premium (GWP) grew 25.9% YoY to ₹6,309.4 crore, led by 32.9% growth in Retail Health.
Retail Health market share expanded to 10.0% in 9M FY26 compared to 9.6% in 9M FY25.
Combined Insurance Service Ratio (CISR) improved to 102.9% from 103.4% YoY, reflecting better operational efficiency.
Individual agent network grew to 224,810, with 15,000 agents added in Q3 FY26 alone.
👀 What to Watch
Investors should view the strong growth in the high-margin retail health segment and the significant jump in profitability as positive indicators. The company's ability to outpace industry growth while improving its combined ratio suggests a sustainable path toward higher return on equity.
Niva Bupa Q3 FY26: 9M PAT Surges 74% to ₹208 Cr; Retail Market Share Hits 10.2%
Niva Bupa reported a robust financial performance for Q3 FY26, with 9M FY26 Profit After Tax (PAT) surging over 74% to ₹208 crore. The company's Gross Written Premium (GWP) on a reported basis grew 55% YoY in Q3 to ₹2,231 crore, while retail health market share expanded to 10.2%. Operational efficiency improved as the Combined Insurance Service Ratio for 9M FY26 decreased by 0.51 percentage points. With 24.5 million lives insured and a 94.1% claim settlement ratio, the company is demonstrating strong scaling and customer retention.
Key Highlights
9M FY26 Profit After Tax (PAT) reached ₹208 crore, a 74% year-on-year surge.
Q3 FY26 Gross Written Premium (GWP) grew 55% YoY to ₹2,231 crore on a reported basis.
Retail health market share increased by 1.4 percentage points YoY to reach 10.2% in Q3 FY26.
Claim Settlement Ratio remained strong at 94.1% for Q3 FY26 with 24.5 million lives insured.
Combined Insurance Service Ratio for 9M FY26 improved by 0.51 percentage points YoY.
👀 What to Watch
Investors should consider the strong growth in retail market share and the significant PAT surge as positive indicators of scaling profitability. Monitor the sustainability of premium growth and the combined ratio in future quarters to assess long-term efficiency.
Niva Bupa Q3 FY26: Gross Premium Jumps 55% YoY; Reports Net Loss of ₹87.6 Crore
Niva Bupa reported a robust 55% YoY growth in Gross Written Premium at ₹2,231.27 crore for Q3 FY26. Despite the top-line growth, the company swung to a net loss of ₹87.64 crore from a profit of ₹13.24 crore in the previous year's quarter. This loss was driven by a significant increase in the incurred claim ratio, which rose to 72.30% from 65.14%. For the nine-month period ended December 2025, the company recorded a total net loss of ₹214.35 crore.
Key Highlights
Gross Premiums Written increased by 54.7% YoY to ₹2,231.27 crore in Q3 FY26.
Net Loss for the quarter stood at ₹87.64 crore compared to a profit of ₹13.24 crore in Q3 FY25.
Incurred Claim Ratio worsened to 72.30% from 65.14% in the corresponding quarter last year.
Solvency Ratio remains healthy at 2.49, though it has declined from 3.03 a year ago.
Combined Ratio remains elevated at 108.19%, indicating continued underwriting losses.
👀 What to Watch
Investors should monitor the rising claim ratios and underwriting losses despite strong premium growth. The company's ability to turn profitable depends on managing its combined ratio and obtaining regulatory forbearance for management expenses.
Niva Bupa: Postal Ballot Results - Independent Director Appointments Approved
Niva Bupa Health Insurance Company Limited announced the results of its postal ballot, with all resolutions passed by the members with the requisite majority on December 04, 2025. Mr. Vivek Anant Karve's appointment as an Independent Director was approved via a special resolution with 99.99% of votes in favor. Ordinary resolutions for the payment of remuneration to Mr. Karve and Mr. Milind Gajanan Barve, Chairman of the Board, were also approved with 99.99% votes in favor. A total of 1,66,65,43,470 votes were casted through remote e-voting facility.
Key Highlights
Appointment of Mr. Vivek Anant Karve as Independent Director approved with 99.99% votes in favor.
Remuneration to Mr. Vivek Anant Karve approved with 99.99% votes in favor.
Remuneration to Mr. Milind Gajanan Barve approved with 99.99% votes in favor.
Total valid votes for resolution 03 were 1,66,65,43,470.
👀 What to Watch
The resolutions have been passed, indicating shareholder approval of the board's proposals. Investors should monitor the company's performance and governance practices following these appointments.
